Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
P/B ratio for Leap Therapeutics, Inc. (LPTX)
P/B ratio as of 2023: 1.41
According to Leap Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.41. At the end of 2022 the company had a P/B ratio of 0.87.
P/B ratio history for Leap Therapeutics, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.41 |
| 2022 | 0.87 |
| 2021 | 2.58 |
| 2020 | 2.86 |
| 2019 | -14.46 |
| 2018 | 3.08 |
| 2017 | 5.14 |
| 2016 | -0.74 |
| 2015 | 4.99 |
| 2014 | 2.02 |
| 2013 | 3.12 |
| 2012 | 4.47 |